Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Exactis Innovation
With
Knight Therapeutics
The proportion of treatment received during all lines of therapy in the metastatic setting will be described. The 2-year survival rate and median OS with interquartile range (IQR) for third-line therapy will be calculated. HRU data and costs during third-line therapy will be collected.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients (≥18 years of age)
Patients with stage IV breast cancer
Patients with HER2+ status in metastatic setting
Patients that received at least two lines of active anti-cancer drugs due to disease progression.
Patients that began third-line therapy prior to October 31, 2018.
You may not be if
Patients treated with an investigational anticancer agent in the ≥ 3rd line setting
Clareo Health | RWD Study in HER2+ mBC Patients in Third-Line Therapy
